1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure

 
• By Sukaina Virji

'No surprise' apparently, as GW Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization, Inc. report negative top-line results from the remaining two Phase III trials of their cannabis extract product Sativex (nabiximols) for the treatment of pain in advanced cancer patients who experience inadequate analgesia during optimized chronic opioid therapy.

'No surprise' apparently, as GW Pharmaceuticals and Otsuka Pharmaceutical Development & Commercialization, Inc. report negative top-line results from the remaining two Phase III trials of their cannabis extract product Sativex (nabiximols) for the treatment of pain in advanced cancer patients who experience inadequate analgesia during optimized chronic opioid therapy.

The result was consistent with data from the first Phase III trial, which had come as a surprise, at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

More from Therapy Areas

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.